跳到正文
Google·· 3 小时前精选

Google 发布健康研究进展:90 篇论文与多项疾病检测成果

Applying technology to understand and treat disease

AI 导读

Google 发布其在健康领域的研究进展,过去五年团队发表 90 篇同行评审论文,累计引用超过 9 万次。其中 AlphaFold 帮助巴塞罗那全球健康研究所虚拟筛选 3 万个化合物,找到两款可重新用于治疗恰加斯病的 FDA 已批准药物;与斯坦福大学医学院合作,用 DeepVariant 和 DeepConsensus 在不到 8 小时内完成全基因组测序诊断。

推荐理由

Google 汇总五年 90 篇健康研究论文与多项落地案例,可了解 AI 在疾病检测与药物发现中的实际进展。

正文 · 原文

Oct 12, 2026

|

In collaboration with scientists and research partners, Google is helping to make disease more detectable, treatable, and preventable — with the goal of improving health outcomes.



A healthcare professional sits at a desk reviewing mammogram scans and medical diagrams on dual computer monitors.

Listen to article

[[duration]] minutes

This content is generated by Google AI. Generative AI is experimental

Google’s health research and tools span from fundamental cellular discovery to laboratory analysis and patient impact. Over the last five years, Google teams have published 90 peer-reviewed research papers about understanding and addressing diseases, accumulating more than 90,000 citations. And building on our vision for how technology can accelerate science to improve lives, we’re collaborating with clinicians, academic institutes, and researchers to ensure discoveries make it out of the lab to benefit patients. Here is how our efforts are helping to advance medical research and public health solutions.

Decoding the mechanics of disease

AlphaGenome Atlas is the most comprehensive catalog of predictions for how single-letter variant changes in the human genome affect molecular biology.

The photo shows a close-up of a petri dish.

To effectively treat an illness, it helps to understand how it operates at the molecular, genetic, and cellular levels. Our early-stage biology models act as collaborative research tools for scientists, revealing nature's hidden mechanics and advancing medical discoveries.

  • Accelerating drug discovery: Researchers at the Institute for Global Health, Barcelona, used AlphaFold to virtually screen 30,000 compounds for antiparasitic activity against Chagas disease, a neglected tropical illness that affects roughly 8 million people and can lead to life-threatening complications if left untreated. This research helped the Institute identify two FDA-approved drugs that could be repurposed for Chagas, expediting time-to-treatment.
  • Mapping genetic variants linked to aging: Identifying which rare genetic changes are linked to specific diseases is challenging because the volume of non-impactful mutations creates "background noise." Researchers at the University of Exeter used AlphaGenome Atlas to search through genomic data from over 54,000 individuals, pinpointing specific variants that drive the abundance of critical proteins circulating in the human body, including PLA2G7 (linked to aging) and EGLN1 (a vital cellular oxygen sensor).
  • Reconstructing the brain at nanoscale: In partnership with Harvard’s Lichtman Lab, we reconstructed a human brain fragment at nanoscale resolution and made the data openly available via Neuroglancer. We additionally mapped the brains of model organisms including the fly, larval zebrafish, and songbird. These neural mapping resources enable researchers to advance their study of brain function.

Accelerating tools for medical solutions

Visual map of proteins developed with the support of AlphaFold.

A man looking at a computer screen displaying a 3D molecular structure with red and green atoms and bonds against a dark background.

The lab is where biological discovery is validated, engineered, and turned into potential medical and public health solutions. Our models have replaced slow, iterative processes with systems that can process large amounts of data quickly and accurately.

  • Supporting genetic diagnoses with ultrarapid genome sequencing: In collaboration with Stanford University School of Medicine, we used DeepVariant and DeepConsensus in a clinical trial to help determine the cause of genetic disease in time-critical cases. The program assisted in enabling life-saving interventions by achieving genetic diagnosis with whole genome sequencing in less than eight hours, an unprecedented achievement also recognized with a Guinness World Record.
  • Designing custom enzymes from scratch: We introduced AlphaProtein Novo, a machine learning pipeline for creating new-to-nature enzymes from first principles. In lab tests, it successfully designed custom enzymes to synthesize key drug motifs, and others to degrade toxic environmental plastics under extreme conditions — demonstrating the ability to design functional proteins that can go beyond what is currently known in nature.
  • Supporting proactive public health initiatives: A community's health is deeply connected to its geography. We are using our Google Earth AI models in combination with environmental, weather, mobility, and other data to help public health leaders forecast disease outbreaks and deliver care to vulnerable communities. In new research from WHO AFRO and the DRC’s INRB, conversational geospatial models replaced weeks of manual coding to help identify Ebola exposure and transmission risks sooner — allowing local responders to proactively deploy mobile laboratories.

Supporting medical providers with machine learning models

New mammography screening systems can help to catch historically missed interval cancers and reduce specialist reading workloads.

A healthcare professional with short dark hair and a light jacket looking at a mammogram scan displayed on a computer screen.

A medical breakthrough only matters if it can help real people. Our research demonstrates that machine learning models can help support disease detection as well as alleviate the administrative workload so providers can focus on care.

  • Flagging historically missed cancer signatures: In a pair of studies published in Nature Cancer in collaboration with Imperial College London and the UK’s National Health Service (NHS), we evaluated a mammography screening system across 125,000 women. The system caught 25% of historically missed interval cancers while showing the possibility of reducing specialist reading workloads by up to 40% — which could help provide crucial relief to healthcare systems facing severe radiologist shortages.
  • Uncovering hidden pediatric leukemia mutations: When applied by Children’s Mercy Hospital to previously sequenced real-world childhood leukemia cases, DeepSomatic confirmed all known variants while detecting 10 previously missed mutations — despite the challenge of working with a tumor-only sample. DeepSomatic is publicly available and has the potential to inform clinical judgments around patient risk and targeted treatments.
  • Predicting global flu surges: A Google flu forecasting model was ranked #1 by the Centers for Disease Control (CDC) for predicting flu-related hospital admissions during the 2025–2026 season. Developed using our Empirical Research Assistance tool, the model outperformed 38 other systems to accurately match observed hospitalizations, showing how the technology can help public health officials anticipate demand for medical services and better prepare for seasonal outbreaks.

Better health within reach for everyone

Transforming health requires scientists, researchers, and institutions working hand-in-hand. That’s why we equip the science community with the advanced models and open-access platforms to fuel breakthrough research — along with the philanthropic funding and computing power they need to apply that research.

Through Google.org, we’re supporting organizations like the Infectious Disease Institute at Makerere University to forecast malaria drug resistance mutations with AlphaFold and AlphaMissense, and the University of Pennsylvania, using AlphaProteo and AlphaFold to help design novel cellular therapies that can augment the treatment of solid tumors and complex diseases. In 2026, Google.org has provided over $60 million to organizations around the world that are applying advanced models to transform how we understand and treat diseases.

By meeting disease at every stage, we can turn the most intractable human health challenges into actionable solutions, helping people everywhere live longer, healthier lives.

Get the latest news from Google in your inbox

Sign up for our newsletters with product updates, event information, special offers, and more.

Your information will be used in accordance with Google's privacy policy. You may opt out at any time.

About the Authors

Yossi Matias

Yossi Matias

VP, Google & GM, Google Research

Yossi Matias is Vice President, Google, and the Head of Google Research. Under Yossi’s leadership, world-class global teams are leading breakthrough research on Foundational Machine Learning & Algorithms, Computing Systems & Quantum Computing, Science, AI for Societal Impact in Health, Climate, Sustainability, Education and Cultural and Behavioral Intelligence. Yossi also leads teams advancing foundational research advancements in Generative AI, including in Factuality and Efficiency, driving real-world impact and shaping the future of technology.

Read less

Pushmeet Kohli

Pushmeet Kohli

VP Science, Google DeepMind & Chief Scientist, Google Cloud

来源:Google · blog.google